journal article·2023

Versatile lipoprotein-inspired nanocomposites rescue Alzheimer's cognitive dysfunction by promoting Aβ degradation and lessening oxidative stress

Hui Wang, Mengmeng Han, Jianfei Li, Yunfeng Hu, Yang Chen, Jin Li

Nanoscale· Volume 15· Issue 38
Publisher page

Abstract

The accumulation of amyloid-β (Aβ) into senile plaques and the resulting continuous oxidative stress are major pathogenic mechanisms in Alzheimer's disease (AD). In this study, we designed a lipoprotein-inspired nanoparticle to facilitate Aβ clearance and alleviate oxidative stress for the treatment of AD. Lipoprotein-like nanocomposites (RLA-rHDL@ANG) were fabricated by assembling reconstituted high density lipoprotein (rHDL) with an apoE-derived peptide (RLA) with Aβ binding and clearance capabilities, and were subsequently camouflaged using reactive oxygen species (ROS)-sensitive DSPE-TK-mPEG2000 and DSPE-TK-PEG3400-ANG with brain penetration as well as ROS scavenging ability. Immunoelectron microscopy, fluorescence colocalization, and enzyme linked immunosorbent assay, together with a thioflavin-T (ThT) fluorescence quantitative test, showed that RLA-rHDL@ANG possessed the ability of high binding affinity to both Aβ monomers and oligomers, and disintegration of pre-formed Aβ aggregates. ROS level monitoring and transmission electron microscopy (TEM) showed that RLA-rHDL@ANG possessed ROS sensitivity and consumption properties. Transcellular assay and in vivo imaging showed that RLA-rHDL@ANG effectively facilitated blood-brain barrier (BBB) penetration and intracerebral accumulation. It promoted the efficient degradation of Aβ by microglia and neurons through lysosomal transport and elimination approaches. Four-week administration of RLA-rHDL@ANG effectively reduced Aβ deposition, decreased the ROS level and improved cognitive functions in AD mice. These findings indicate that multifunctional RLA-rHDL@ANG may serve as a promising and feasible candidate for managing the progression of AD.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Alzheimer's disease research and treatments · Cholinesterase and Neurodegenerative Diseases · Tryptophan and brain disorders

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Pharmacy, Xuzhou Medical University, Xuzhou 221004, China

Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou 221004, China

Funding

Government of Jiangsu Province · National Natural Science Foundation of China

References (33)

Show source-provided references
1. Saido · Proc. Jpn. Acad., Ser. B · 2013 · 89 · 32110.2183/pjab.89.321 ↗
2. Liebscher · Front. Psychiatry · 2012 · 3 · 2610.3389/fpsyt.2012.00026 ↗
3. Mattson · Nature · 2004 · 430 · 63110.1038/nature02621 ↗
4. Faustino · Pharmacol. Res. · 2017 · 120 · 6810.1016/j.phrs.2017.03.020 ↗
5. Dubois · Lancet Neurol. · 2014 · 13 · 61410.1016/S1474-4422(14)70090-0 ↗
6. Buckner · J. Neurosci. · 2005 · 25 · 770910.1523/JNEUROSCI.2177-05.2005 ↗
7. Selkoe · Science · 2002 · 298 · 78910.1126/science.1074069 ↗
8. Castellano · Sci. Transl. Med. · 2011 · 3 · 89ra5710.1126/scitranslmed.3002156 ↗
9. Liao · Small · 2012 · 8 · 363110.1002/smll.201201068 ↗
10. Haass · Cold Spring Harb. Perspect Med. · 2012 · 2 · a00627010.1101/cshperspect.a006270 ↗
11. Mawuenyega · Science · 2010 · 330 · 177410.1126/science.1197623 ↗
12. Wisniewski · Neuron · 2015 · 85 · 116210.1016/j.neuron.2014.12.064 ↗
13. Huang · ACS Nano · 2015 · 9 · 1080110.1021/acsnano.5b03124 ↗
14. Song · ACS Nano · 2014 · 8 · 234510.1021/nn4058215 ↗
15. Koffie · Proc. Natl. Acad. Sci. U. S. A. · 2011 · 108 · 1883710.1073/pnas.1111405108 ↗
16. Zensi · J. Controlled Release · 2009 · 137 · 7810.1016/j.jconrel.2009.03.002 ↗
17. Cramer · Science · 2012 · 335 · 150310.1126/science.1217697 ↗
18. Hanson · JAMA Neurol. · 2013 · 70 · 97210.1001/jamaneurol.2013.396 ↗
19. Matsubara · Neurobiol. Aging · 2004 · 25 · 83310.1016/j.neurobiolaging.2003.10.004 ↗
20. Oh · Int. J. Mol. Sci. · 2020 · 21 · 80210.3390/ijms21030802 ↗
21. Bana · Nanomedicine · 2014 · 10 · 158310.1016/j.nano.2013.12.001 ↗
22. Re · J. Biotechnol. · 2011 · 156 · 34110.1016/j.jbiotec.2011.06.037 ↗
23. Gackowski · J. Neurol. Sci. · 2008 · 266 · 5710.1016/j.jns.2007.08.041 ↗
24. Heppner · Nat. Rev. Neurosci. · 2015 · 16 · 35810.1038/nrn3880 ↗
25. Jia · ACS Appl. Mater. Interfaces · 2021 · 13 · 4960210.1021/acsami.1c06687 ↗
26. Rosini · J. Med. Chem. · 2014 · 57 · 282110.1021/jm400970m ↗
27. Xue · R. Soc. Open Sci. · 2017 · 4 · 16069610.1098/rsos.160696 ↗
28. Bobo · Biochim. Biophys. Acta, Gen. Subj. · 2017 · 1861 · 116810.1016/j.bbagen.2017.03.001 ↗
29. Mantyla · Eur. J. Pharm. Sci. · 2004 · 23 · 15110.1016/j.ejps.2004.06.006 ↗
30. Wang · Iran. J. Basic Med. Sci. · 2017 · 20 · 474
31. Lu · Adv. Sci. · 2019 · 6 · 180158610.1002/advs.201801586 ↗
32. Saeki · Biochem. J. · 2002 · 368 · 70510.1042/bj20020101 ↗
33. Kong · Cell. Mol. Life Sci. · 2010 · 67 · 181710.1007/s00018-010-0277-y ↗